
Keywords: SDDs; stimulant designer drugs; 4-BMC; 4-bromomethcathinone; 4-CMC; 4-chloromethcathinone; mCPP; m-chlorophenyl-piperazine; EDDP; 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine; 4F-α-PEP; 4-fluoro-α-pyrrolidinoheptiophenone; 2-FMC; 2-fluoromethcathin